1
Arterburn Linda, Benisek Diane, Hoffman James, Oken Harry A, Van, Elswyk Mary: Docohexaenoic acid for improved glycemic control. Martek Biosciences Corporation, Arterburn Linda, Benisek Diane, Hoffman James, Oken Harry A, Van, Elswyk Mary, POSORSKE Laurence H, April 8, 2004: WO/2004/028469 (5 worldwide citation)

This invention is directed to methods of treating patients with metabolic syndrome, prediabetes and/or Type 11 diabetes mellitus by administering docosahexaenoic acid (DHA) alone or in combination with diabetes-related medications.


2
Arterburn Linda M, Hoffman James P, Oken Harry A, Van, Elswyk Mary: Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation. Martek Biosciences Corporation, Arterburn Linda M, Hoffman James P, Oken Harry A, Van, Elswyk Mary, POSORSKE Laurence H, April 8, 2004: WO/2004/028470 (2 worldwide citation)

This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The meth ...


3
Arterburn Linda M, Hoffman James P, Oken Harry A, Van Elswyk Mary: Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation. Martek Biosciences, July 13, 2005: EP1551382-A2

This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The meth ...


4
ARTERBURN LINDA M, HOFFMAN JAMES P, OKEN HARRY A, VAN ELSWYK MARY: [fr] Acide docosahexaénoïque pour le traitement des inflammations sous-cliniques, [de] Docosahexaensäure zur Behandlung von subklinischen Entzündungen, [en] Docosahexaenoic acid for treating subclinical inflammation. MARTEK BIOSCIENCES, February 16, 2011: EP2283837-A2

[en] This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The ...


5
ARTERBURN LINDA M, HOFFMAN JAMES P, OKEN HARRY A, VAN ELSWYK MARY: [fr] Acide docosahexaénoïque pour le traitement des inflammations sous-cliniques, [de] Docosahexaensäure zur Behandlung von subklinischen Entzündungen, [en] Docosahexaenoic acid for treating subclinical inflammation. MARTEK BIOSCIENCES, February 16, 2011: EP2283838-A2

[en] This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The ...


6
Arterburn Linda, Benisek Diane, Hoffman James, Oken Harry A, Van Elswyk Mary: Improved glycemic control for prediabetes and/or diabetes type ii using docosahexaenoic acid. Martek Biosciences, August 3, 2005: EP1558237-A2

This invention is directed to methods of treating patients with metabolic syndrome, prediabetes and/or Type 11 diabetes mellitus by administering docosahexaenoic acid (DHA) alone or in combination with diabetes-related medications.